| Prev Close | 10.39 |
| Open | 10.50 |
| Day Low/High | 10.14 / 10.77 |
| 52 Wk Low/High | 5.21 / 22.20 |
| Volume | 631.76K |
| Avg Volume | 1.12M |
| Exchange | NASDAQ |
| Shares Outstanding | 39.84M |
| Market Cap | 434.70M |
| EPS | -1.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Think Big on These Small Biotechs
New drugs give small-cap companies opportunity to expand markets and revenues.
Don't Roll the Dice on Central Bank News
The bears are trying it out on the Bank of England news today, but they may get squeezed.
Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts
The new deals signal a long-term commitment from two of the largest biotech companies to focus on cancer immunotherapy as a platform for future growth.
Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
Collaboration Will Advance Highly Targeted, Patient-Specific Treatment Approach
Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study
A type of common bacteria re-engineered by Aduro Biotech to engage the immune system to kill pancreatic cancer failed a mid-stage study, the company announced Monday.
These 5 Stocks Are Poised for Breakouts
These stocks look ready to break out and trade higher from current levels.
Late Breaking Data At AACR Annual Meeting From Advaxis Phase 2 Study Of AXAL Highlights Potential Of The Company's Lm Technology™ Platform
First clinical data with AXAL to show evidence of cytotoxic T cell infiltration into the tumor immune microenvironment or TME for HPV-Positive oropharyngeal cancer